جستجوی استاد راهنمای دانشگاهی

Ross L. Levineمشاهده پروفایل

استاد

• Hematology
• Oncology
• Genetics
• +۴ مورد دیگر

Ross L. Levine, MD, is a distinguished Professor and Physician-Scientist at Memorial Sloan Kettering Cancer Center (MSKCC), holding the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes (MDS). As Senior Vice President of Memorial Hospital’s Translational Research division, he leads groundbreaking work in hematologic malignancies, particularly leukemia and myeloproliferative neoplasms (MPNs). His research integrates clinical care with genomic and molecular studies to develop targeted therapies. Levine received his MD from Johns Hopkins University School of Medicine, followed by residency in Internal Medicine at Massachusetts General Hospital and fellowship in Hematology/Oncology at Dana-Farber Cancer Institute. Education: MD, Johns Hopkins University School of Medicine Residencies: Internal Medicine, Massachusetts General Hospital Fellowships: Hematology/Medical Oncology, Dana-Farber Cancer Institute Levine’s research focuses on the genetic and epigenetic drivers of myeloid cancers, including JAK-STAT pathway mutations in MPNs and AML. His team explores therapeutic strategies targeting CXCL8/CXCR2 signaling and clonal hematopoiesis. Key contributions include identifying JAK2 mutations in MPNs and advancing single-cell mutation analysis for clonal evolution studies. His clinical expertise includes treating patients with acute myeloid leukemia (AML), polycythemia vera, and myelofibrosis, performing bone marrow biopsies, and leading clinical trials for targeted therapies. Levine has pioneered translational research programs linking lab discoveries to patient care, emphasizing precision medicine. Awards & Honors: Pershing Square Sohn Prize (2014), Howard Hughes Medical Institute Early Career Award (2007), and multiple Leukemia & Lymphoma Society accolades. He holds leadership roles in professional societies, including co-chairing the American Society of Hematology’s 2016 Scientific Program. Levine’s lab, part of the Human Oncology & Pathogenesis Program (HOPP), collaborates with institutions globally. His work has been published in high-impact journals like Cancer Cell , Nature , and Blood , advancing understanding of cancer genetics and therapeutic innovation.

• Machine Learning
• Bioinformatics
• Deep Generative Models
• +۳ مورد دیگر

Anders Krogh is a Professor at the Department of Computer Science, University of Copenhagen, and also holds a position at the Department of Public Health in the Section for Health Data Science and AI. He serves as the head of the Center for Health Data Science (HeaDS) in the Faculty of Health and Medical Sciences. Previously, he was affiliated with the Department of Biology at the University of Copenhagen until 2020. Dr. Krogh earned his PhD in theoretical physics but transitioned into machine learning and bioinformatics during his doctoral studies. His research spans both theoretical foundations and practical applications in these fields. He is particularly renowned for his pioneering work on hidden Markov models for biological sequences, which has had significant impact in computational biology. In recent years, Krogh's research has focused on deep generative models applied to gene expression data and other biomedical applications. His work bridges computer science with healthcare, developing AI-driven approaches for precision medicine, cancer diagnostics, and analysis of complex biological systems. His current research integrates machine learning with quantum computing applications in biomolecular modeling. Analysis of his recent publications reveals a strong trend toward applying artificial intelligence to healthcare challenges, particularly in rare diseases, cancer diagnostics, and personalized medicine. His work increasingly incorporates federated learning approaches to address privacy concerns while enabling collaborative research across institutions. There's also a growing emphasis on quantum computing applications in biomolecular modeling and drug discovery. As head of the Center for Health Data Science, Krogh leads interdisciplinary research efforts that bring together computer scientists, medical researchers, and clinicians. His team develops novel computational frameworks like MOSAIC for multimodal analysis of rare cancers and multiDGD for multi-omics data integration. These tools are designed to translate AI innovations into clinical practice while addressing the unique challenges of medical data.

Fnu Aakashمشاهده پروفایل

استادیار

• Hematopathology
• Oncology
• Cancer Diagnostics
• +۲ مورد دیگر

Dr. Fnu Aakash serves as Interim Director of Hematopathology and Assistant Professor in the Department of Pathology at the University of Texas Medical Branch. His research focuses on hematopathology, oncology diagnostics, and clinical significance of neoplastic disorders. With an h-index of 55, Aakash has contributed significantly to cancer classification systems through publications in Modern Pathology and American Journal of Surgical Pathology. His recent work includes developing international consensus guidelines for myelodysplastic neoplasms and characterizing non-neoplastic changes associated with breast implants. Research collaborations span multiple institutions including MD Anderson Cancer Center, with specialization in malignant hematology and lymphoma diagnostics.

Andrew L. Feldmanمشاهده پروفایل

استاد

• Molecular Pathogenesis
• T-cell Lymphoma
• Lymphoma Genetics
• +۵ مورد دیگر

Andrew L. Feldman, MD , is a Professor of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, Minnesota. He specializes in the molecular pathogenesis of T-cell lymphomas, focusing on genetic abnormalities, biomarkers, and individualized therapies. His work bridges next-generation sequencing (NGS) infrastructure and translational research to improve lymphoma diagnosis and subclassification. Primary Appointment: Consultant, Division of Hematopathology Joint Appointment: Consultant, Division of Experimental Pathology and Laboratory Medicine Education: MD, Brown University (1991) BA, Brown University (1986) Clinical Fellowship, Hematopathology, National Cancer Institute (2006) Research Interests: Dr. Feldman's research explores the genetic basis of T-cell lymphomas, which are often fatal. By characterizing mutations (e.g., DUSP22 , TP63 , STAT3 ) and applying bioinformatics, his team develops diagnostic tests to predict therapeutic responses. He also investigates how genetic heterogeneity impacts lymphoma classification and treatment strategies. Scientific Awards: Berard-Dorfman Founders Award, Society for Hematopathology (2015) Recipient Medal, Pedro Ruiz Gallo National University, Peru (2007) Artemis Fellowship, Nikolas Symposium XV, Athens (2005) NIH Fellows Award for Research Excellence (2003, 2000) First Prize, Resident Paper Competition (1999) Daland Award, New England Cancer Society (1999) Outstanding Junior Resident Teaching Award (1996) Joseph Collins Foundation Scholarship (1988) Advising and Grants: Dr. Feldman has directed the Mayo Clinic Biospecimens Core and led NCI-funded projects like the Lymphoma Specialized Program of Research Excellence (SPORE) and Molecular Classification of Anaplastic Large Cell Lymphoma . He has served on NCI Lymphoma Steering Committee and Mayo Clinic's NGS Infrastructure Subcommittee. Laboratory and Collaborations: His lab collaborates with the International Lymphoma Study Group , Mayo Clinic Comprehensive Cancer Center , and Association for Molecular Pathology . He co-developed clinical trials linking molecular profiling to therapeutic targets and contributed to the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) Research Consortium.

Mahdi S. Hosseiniمشاهده پروفایل

استادیار

• Deep Learning
• Computer Vision
• Computational Pathology
• +۳ مورد دیگر

Mahdi S. Hosseini is an Assistant Professor in the Department of Computer Science and Software Engineering at Concordia University and a faculty member of the Applied AI Institute. He holds a PhD from the University of Toronto (2016) and completed a postdoctoral fellowship at UofT, supported by MITACS-Elevate and NSERC fellowships. His research focuses on advancing deep learning and computer vision for computational pathology and healthcare technologies, aiming to develop AI tools for clinical diagnosis. He currently supervises graduate students and has published over 30 papers and two patents. Education: PhD in Electrical and Computer Engineering from the University of Toronto (2016), postdoctoral training at UofT collaborating with Huron Digital Pathology Inc. (Waterloo, Ontario). Research interests include deep learning, computer vision, computational pathology, medical imaging, and AI ethics (P4AI project). His work emphasizes developing explainable AI systems for clinical pathology, biomarker discovery, and efficient learning algorithms. Professional service includes serving as Area Chair for NeurIPS 2023, CVPR 2023-2024, and ECCV 2024. He reviews grants for CIHR, NSERC, and serves on program committees for key conferences (ICCV, CVPR, NeurIPS). Teaching includes courses on applied AI, machine learning, and deep learning for computational pathology at both graduate and undergraduate levels. Awards: MITACS-Elevate Fellowship (postdoc), NSERC Research Funding (2016-2017). His work has led to patents in diagnostic systems and has collaborated with hospitals and pathologists to advance clinical applications. Labs/Teams: Active collaborations with the Applied AI Institute at Concordia, Huron Digital Pathology, and healthcare institutions. Research emphasizes interdisciplinary approaches between computer science and clinical medicine.

• Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• +۴ مورد دیگر

Nikolai Podoltsev, MD, PhD, is an Associate Professor of Medicine (Hematology) at Yale University School of Medicine. He serves as the Associate Director of the Hematology/Oncology Fellowship Program and Clinical Director of Malignant Hematology within the Department of Internal Medicine. Dr. Podoltsev is also the director of the Hematology/Leukemia Tumor Board and represents Yale Cancer Center on National Comprehensive Cancer Network (NCCN) clinical practice guidelines panels, including the Myeloproliferative Neoplasms Panel. Dr. Podoltsev's research focuses on the management of patients with acute leukemias (including acute myeloid leukemias and acute lymphoblastic leukemia), myeloid neoplasms (such as myelodysplastic syndromes and myeloproliferative neoplasms), and bone marrow failure syndromes. His work spans clinical research, epidemiology, and patterns of care for patients with hematological malignancies. As a principal investigator, he leads multiple clinical trials enrolling patients with acute leukemias and myeloid malignancies. Analysis of Dr. Podoltsev's recent publications (2024-2025) reveals a strong focus on therapeutic advancements in myeloid malignancies, particularly acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis. His research spans drug development (including novel agents like imetelstat and luspatercept), combination therapies, treatment sequencing, and cost-effectiveness analyses. There is a clear emphasis on translating molecular understanding into clinical applications, with significant work on targeted therapies for specific genetic mutations. Yale Cancer Center Award for Clinical Excellence (2022) The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology (2021, 2017, 2011) As the Associate Director of the Yale Hematology/Oncology Fellowship Program and Yale-New Haven Hospital Duffy Firm Chief for Education, Dr. Podoltsev plays a pivotal role in hematology education for fellows, residents, and medical students. He is actively involved in multiple clinical trials through the Leukemia Clinical Research Team and the Yale Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, which enables him to study epidemiology and patterns of care for hematological malignancies. Dr. Podoltsev is part of the Leukemia Disease Aligned Research Team (DART) at Yale Cancer Center, where he contributes to advancing treatment options for patients with blood cancers. His clinical expertise spans the full spectrum of malignant hematology with a particular focus on older adult patients.

• Hematopathology
• Molecular Diagnostics
• Flow Cytometry
• +۷ مورد دیگر

Alexa Siddon, MD, is an Assistant Professor in the Department of Laboratory Medicine at Yale School of Medicine, with secondary appointments in Pathology. She serves as Hematopathology Fellowship Director, Director of the Molecular Diagnostics Laboratory, Director of Flow Cytometry, and Associate Director of the Hematology Laboratory. She is also affiliated with the Yale Cancer Center, Clinical Flow Cytometry Laboratory, and the Hematopathology Laboratory at the Veteran Affairs Connecticut Healthcare System. Dr. Siddon's research focuses on hematopathology, particularly myeloid malignancies, acute leukemias, and post-transplant monitoring. Her work integrates molecular diagnostics, flow cytometry, and genomic analysis to improve patient diagnosis and outcomes. She has co-authored over 10 peer-reviewed articles in recent years, frequently collaborating with leading hematologists and pathologists such as Christopher Tormey, Henry Rinder, and Rory Shallis. Her publications reveal a strong trend in translational research, emphasizing the clinical implications of genetic mutations (e.g., TP53, NPM1, IDH1/2), chimerism testing post-transplant, and immunophenotypic characterization of hematologic malignancies. The research spans disciplines including oncology, molecular biology, immunology, and clinical pathology, with a clear focus on precision diagnostics and prognostic modeling. Scientific Awards: ASCP Distinguished Educator Award Paul J. Strandjord Young Investigator Award Donald H. Buchholz Research Prize Dr. Siddon is actively involved in medical education, directing fellowship programs and mentoring trainees. She has no reported grants listed in the text, but her leadership in diagnostic laboratories and active publication record suggest ongoing research funding. She is not part-time, not retired, and remains a current, active faculty member. She is affiliated with multiple research entities including the Cancer Immunology Center, Center for Biomedical Data Science, and the Yale Cancer Center, contributing to interdisciplinary teams focused on hematologic malignancies and diagnostic innovation.

Ananya Choudhuryمشاهده پروفایل

استاد

• Radiation Therapy
• Prostate Cancer
• Bladder Cancer
• +۹ مورد دیگر

Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.

• Apoptosis
• Biochemistry
• Breast Neoplasms
• +۵ مورد دیگر

Professor Faye Rogers serves as Professor of Therapeutic Radiology at Yale University School of Medicine, holding multiple leadership positions including Associate Cancer Center Director for YCC Collaborative Excellence, Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her work bridges radiation oncology, DNA repair mechanisms, and cancer therapeutics within Yale's comprehensive cancer research ecosystem. PhD from University of Maryland at Baltimore (1998) Postdoctoral Fellow at Yale School of Medicine Dr. Rogers' research focuses on the intersection of DNA repair mechanisms and cancer therapeutics, with particular expertise in triplex DNA structures, genomic instability, and targeted cancer therapies. Her work explores how DNA damage responses can be leveraged for therapeutic benefit, especially in breast neoplasms and other malignancies. Through her leadership in the DNA Damage and Genome Integrity program, she investigates novel approaches to disrupt cancer cell survival mechanisms while sparing healthy tissue. Her research has significant implications for radiation oncology, particularly in developing more precise and effective radiation-based treatments. Analysis of Dr. Rogers' publication record reveals a consistent trajectory in DNA repair mechanisms and cancer therapeutics, with increasing focus on translational applications. Her work demonstrates expertise in triplex DNA structures, RAD51 inhibition, and synthetic lethality approaches. Recent publications show a shift toward more clinically applicable research, particularly in targeting DNA repair pathways in specific cancer subtypes like IDH1-mutant cancers and PTEN-deficient glioblastomas. Her collaborative work with Peter Glazer and others demonstrates strong interdisciplinary connections between radiation oncology, molecular biology, and drug development. Leadership in Diversity, Equity & Inclusion Award (Yale School of Medicine, 2022) Translational Science Research Prize (Yale Cancer Center, 2022) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a pivotal role in mentoring the next generation of physician-scientists and supporting underrepresented minorities in biomedical research. Her leadership in collaborative excellence initiatives demonstrates commitment to fostering interdisciplinary research teams across Yale's scientific ecosystem. Through the YCC Collaborative Excellence program, she has secured significant funding for innovative cancer research that bridges basic science and clinical applications, particularly in the areas of DNA repair targeting and radiation oncology. Dr. Rogers leads research within Yale's Therapeutic Radiology department, with strong connections to the Radiobiology program and the Yale Cancer Center. Her work is integrated with the Program in Translational Biomedicine and the Yale Combined Program in the Biological and Biomedical Sciences. Through the BioMed Amgen Scholars Program, she provides critical research opportunities for undergraduate students, particularly those from underrepresented backgrounds, fostering talent in DNA repair research and cancer therapeutics.

• Cancer Genomics
• Liquid Biopsies
• Machine Learning in Oncology
• +۷ مورد دیگر

Ash A. Alizadeh is the Moghadam Family Professor of Medicine, Oncology, and Hematology (by courtesy) at Stanford University, where he serves as leader of the Cancer Genomics Program at Stanford Cancer Institute. He holds multiple academic appointments including Professor in Medicine - Oncology, and membership in Bio-X, the Institute for Stem Cell Biology and Regenerative Medicine, and the Maternal & Child Health Research Institute (MCHRI). Dr. Alizadeh received his BS in Biochemistry from UCLA (1994), MD from Stanford Medical School, and PhD in Biophysics from Stanford. He completed additional training at the National Cancer Institute (NCI), the National Institutes of Health (NIH), and the Howard Hughes Medical Institute (HHMI). His primary research focuses on developing and applying genome technologies and computing (machine learning & data science) to problems in human disease, with special emphasis on cancer detection, classification, monitoring, and tumor immunology. His laboratory pioneers noninvasive cancer genomic techniques including CAPP-Seq, PhasED-Seq, and EPIC-Seq for "liquid biopsies" that analyze circulating nucleic acids for early cancer detection and monitoring therapeutic response. Using machine learning approaches, his group studies how cellular compositional variation impacts cancer behavior and therapeutic response, including anti-tumor immunity. His work spans molecular, cellular, organism and population levels of tumor behavior analysis. Dr. Alizadeh has received numerous prestigious awards including the Scholar Award from the American Society of Hematology (ASH), the Leukemia & Lymphoma Society (LLS), the V-Foundation, as well as awards from the American Red Cross, Damon Runyon Cancer Research Foundation, and Doris Duke Charitable Research Foundation. He is an elected member of the American Society for Clinical Investigation (ASCI) and serves on the Scientific Advisory Board of the Lymphoma Research Foundation (LRF). As an educator and mentor, Dr. Alizadeh advises numerous doctoral students, postdoctoral fellows, and medical scholars. He teaches in the Department of Medicine and Immunology and serves on various admissions panels at Stanford. His laboratory, the Alizadeh Lab, is a hub for interdisciplinary cancer genomics research that combines computational biology, molecular genetics, and clinical oncology to develop novel cancer diagnostics and therapeutics.

• Veterinary Clinical Pathology
• Feline Health
• Canine Health
• +۳ مورد دیگر

Associate Professor Natalie Courtman-Kalms is a specialist veterinary clinical pathologist at the Sydney School of Veterinary Science, University of Sydney. Her expertise spans clinical pathology research across domestic animals, wildlife, and production species, with a focus on feline, canine, and avian health. She holds qualifications including BVSc, MANZCVS, MVS GCUT, and Dip ACVP. Research interests include diagnostic methodologies in hematology, coagulation studies, and oncological pathology in avian species. She leads the Veterinary Pathology Diagnostic Services (VPDS) and has secured grants such as the 2023 PARR clonality assay project investigating lymphoma and inflammatory bowel disease in cats. Her work bridges clinical practice and research, contributing to improved diagnostic approaches in veterinary medicine. She has published on analytical errors in veterinary diagnostics, species-specific biomarkers, and avian neoplasms.

Rafael Pereraمشاهده پروفایل

استاد

• Medical Statistics
• Primary Care Health Sciences
• Monitoring of Long-Term Conditions
• +۶ مورد دیگر

Rafael Perera is a Professor of Medical Statistics at the Nuffield Department of Primary Care Health Sciences (NDPCHS), University of Oxford, where he has been since 2002. He holds leadership roles as Director of the Statistics Group and Director of Graduate Studies , overseeing academic leadership and methodological research. He is also a Statistical Editor of BMJ and BMJ Medicine , and a fellow at St Hugh’s College Oxford . Education : DPhil, MSc, MA Rafael’s research focuses on monitoring for managing long-term conditions (e.g., Type 2 diabetes, hypertension) and complex multimorbidity phenotypes . His work includes impact of extreme temperatures on health , meta-analysis methods , and methodology for infectious diseases . He leads large methodological groups and has been a PI on NIHR-funded infrastructure programs (BRC, ARC, MIC). Recent publications highlight his expertise in clinical prediction models , digital health interventions , and diagnostic test evaluation . His grants span applied research , global health transformation , and ageing research . Scientific Awards : National and international recognition for methodology development in clinical trials (NIHR Progress Report 2008/09) Rafael supervises DPhil and MSc students and leads a fully accredited Clinical Trials Unit . His editorial and policy influence extends to healthcare policy panels and the Centre for Evidence-Based Medicine as Director of Research Methodologies.

Kyle W. Klarichمشاهده پروفایل

استاد

• Structural Heart Disease
• Cardiac Tumors
• Hypertrophic Cardiomyopathy
• +۲ مورد دیگر

Kyle W. Klarich is Professor of Medicine and consultant in both the Division of Structural Heart Disease and Division of Echocardiography at Mayo Clinic. His clinical practice and research focus on structural heart disease, cardiac tumors, hypertrophic cardiomyopathies, and valvular heart disease. Dr. Klarich investigates complications prevention and quality-of-life improvement for patients with rare cardiac conditions. As Cardiovascular Disease Fellowship program director since 2010, he is extensively involved in medical education and has received multiple teaching awards including the ACGME's Parker J. Palmer Courage to Teach Award finalist recognition.

Erwin Schoofمشاهده پروفایل

دانشیار

• Proteomics
• Mass Spectrometry
• Single-Cell Analysis
• +۷ مورد دیگر

Erwin Schoof is an Associate Professor at the Department of Biotechnology and Biomedicine , Technical University of Denmark. He leads the Cell Diversity Lab and focuses on advancing proteomics and mass spectrometry technologies. Expertise in single-cell proteomics , stem cell niches , and bioinformatics . Active in myelofibrosis and leukemia research , with applications in UN Sustainable Development Goals . Research Trends from 2025–2024 include: Machine learning-driven peptide sequencing (InstaNovo, InstaNexus). Single-cell resolution tools for mapping hematopoietic stem cells and tumor microenvironments . Biomarker discovery in chronic diseases and respiratory conditions . Supervision : Mentors multiple PhD students on single-cell proteomics , omics data analysis , and biotherapeutic production . Labs & Collaborations : Collaborates with international teams on plasma proteomics , 3D bioengineering , and advanced mass spectrometry workflows .

Sally B. Coburnمشاهده پروفایل

پژوهشگر

• Epidemiology
• HIV and AIDS
• Cancer Etiology and Risk Factors
• +۸ مورد دیگر

Sally B. Coburn, PhD, MPH, is an Assistant Scientist in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. Her research focuses on cancer outcomes and etiology in people living with HIV, with a strong emphasis on health disparities, longitudinal data, and the use of electronic health records (EHR) in large collaborative studies such as the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) and IeDEA. PhD, Johns Hopkins University, 2021 MPH, George Washington University, 2015 BS, George Washington University, 2013 Her research interests include HIV, AIDS, HIV and aging, cancer outcomes and risk factors, health disparities, EHR data, and collaborative study design. She employs epidemiologic and statistical methods to understand mechanisms of disease and population-level implications for people with HIV in North America. The trends in her recent publications (2021–2025) reflect a strong focus on cancer risk, comorbidities, and treatment outcomes in HIV populations. Her work spans breast cancer, non-AIDS-defining cancers, anemia, statin use, and hormonal health in women with HIV. She frequently collaborates on large cohort studies and contributes to understanding the long-term health impacts of HIV and antiretroviral therapy. No scientific awards or prizes are mentioned in the provided text. Sally Coburn is actively involved in research grants and collaborative projects, particularly through NA-ACCORD and IeDEA. While no formal advisees are listed, her role as a researcher suggests mentorship within collaborative teams. She contributes to advancing public health knowledge through methodologically rigorous observational studies. She is affiliated with major research initiatives including the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), which enables large-scale, multi-site epidemiological research on HIV and associated conditions.